Context Therapeutics Inc. (NASDAQ:CNTX) shares fell 30.45% in Wednesday’s after-hours session after the company reported its second-quarter financial results.
The stock closed Wednesday’s regular session up 11.45% at $0.69 before falling 30.45% to $0.48 in after-hours trading.
Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell-engaging bispecific antibodies for solid tumors. Its lead programs include CTIM-76 and CT-202.
Quarter Results
For the quarter ended June 30, 2026, Context Therapeutics reported a net loss of $14.6 million, compared with $8.8 million in the prior-year period. Research and development expenses increased to $12.5 million from $7.8 million, while general and administrative expenses rose to $2.4 million from $1.9 million.
The company ended the quarter with $43 million in cash and cash equivalents and said it expects its existing cash to fund operations into the fourth quarter of 2027.
Context also announced it is discontinuing development of CT-95 to prioritize its CTIM-76 and CT-202 programs. The company expects initial clinical data from its prioritized pipeline beginning in the second quarter of 2027 and plans to dose the first patient in the Phase 1 trial of CT-202 during the third quarter of 2026.
Trading Metrics
Context Therapeutics has a market capitalization of approximately $63.86 million, with a 52-week high of $3.62 and a 52-week low of $0.55.
Over the past 12 months, CNTX shares are down approximately 1%. On a year-to-date basis the stock has declined over 55%.
Benzinga Edge Stock Rankings show negative price trends across the short-, medium- and long-term time frames.
Disclaimer: This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: renderis studio / Shutterstock
Login to comment